|
1
|
Ligier K, Belot A, Launoy G, Velten M,
Bossard N, Iwaz J, Righini CA, Delafosse P and Guizard AV: network
Francim: Descriptive epidemiology of upper aerodigestive tract
cancers in France: Incidence over 1980–2005 and projection to 2010.
Oral Oncol. 47:302–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takes RP, Strojan P, Silver CE, Bradley PJ
Jr, Haigentz M Jr, Wolf GT, Shaha AR, Hartl DM, Olofsson J,
Langendijk JA, et al: International Head and Neck Scientific Group:
Current trends in initial management of hypopharyngeal cancer: The
declining use of open surgery. Head Neck. 34:270–281. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoffman HT, Karnell LH, Shah JP, Ariyan S,
Brown GS, Fee WE, Glass AG, Goepfert H, Ossoff RH and Fremgen AM:
Hypopharyngeal cancer patient care evaluation. Laryngoscope.
107:1005–1017. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Godballe C, Jørgensen K, Hansen O and
Bastholt L: Hypopharyngeal cancer: Results of treatment based on
radiation therapy and salvage surgery. Laryngoscope. 112:834–838.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee MS, Ho HC, Hsiao SH, Hwang JH, Lee CC
and Hung SK: Treatment results and prognostic factors in locally
advanced hypopharyngeal cancer. Acta Otolaryngol. 128:103–109.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chung EJ, Lee SH, Baek SH, Park IS, Cho SJ
and Rho YS: Pattern of cervical lymph node metastasis in medial
wall pyriform sinus carcinoma. Laryngoscope. 124:882–887. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: Multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mochizuki S and Okada Y: ADAMs in cancer
cell proliferation and progression. Cancer Sci. 98:621–628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins - therapeutic potential in cancer. Curr Cancer Drug
Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Murphy G: The ADAMs: Signalling scissors
in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klein T and Bischoff R: Active
metalloproteases of the A disintegrin and metalloprotease (ADAM)
family: Biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saftig P and Lichtenthaler SF: The alpha
secretase ADAM10: A metalloprotease with multiple functions in the
brain. Prog Neurobiol. 135:1–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vincent B: Regulation of the α-secretase
ADAM10 at transcriptional, translational and post-translational
levels. Brain Res Bull. 126:154–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Janes PW, Saha N, Barton WA, Kolev MV,
Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M
and Nikolov DB: Adam meets Eph: An ADAM substrate recognition
module acts as a molecular switch for ephrin cleavage in trans.
Cell. 123:291–304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reiss K, Maretzky T, Ludwig A, Tousseyn T,
de Strooper B, Hartmann D and Saftig P: ADAM10 cleavage of
N-cadherin and regulation of cell-cell adhesion and beta-catenin
nuclear signalling. EMBO J. 24:742–752. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maretzky T, Reiss K, Ludwig A, Buchholz J,
Scholz F, Proksch E, de Strooper B, Hartmann D and Saftig P: ADAM10
mediates E-cadherin shedding and regulates epithelial cell-cell
adhesion, migration, and beta-catenin translocation. Proc Natl Acad
Sci USA. 102:9182–9187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moss ML, Stoeck A, Yan W and Dempsey PJ:
ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol.
9:2–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang W, Liu S, Liu K, Wang Y, Ji B, Zhang
X and Liu Y: A disintegrin and metalloprotease (ADAM)10 is highly
expressed in hepatocellular carcinoma and is associated with tumour
progression. J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
You B, Shan Y, Shi S, Li X and You Y:
Effects of ADAM10 upregulation on progression, migration, and
prognosis of nasopharyngeal carcinoma. Cancer Sci. 106:1506–1514.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo J, He L, Yuan P, Wang P, Lu Y, Tong F,
Wang Y, Yin Y, Tian J and Sun J: ADAM10 overexpression in human
non-small cell lung cancer correlates with cell migration and
invasion through the activation of the Notch1 signaling pathway.
Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
|
|
21
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu L, Liu N, Han Y, Xie C, Li Q and Wang
E: ADAM10 regulates proliferation, invasion, and chemoresistance of
bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jing P, Sa N and Xu W: miR-140-5p affects
the migration and invasion of hypopharyngeal carcinoma cells by
downregulating ADAM10 expression. Zhonghua Er Bi Yan Hou Tou Jing
Wai Ke Za Zhi. 51:189–196. 2016.(In Chinese). PubMed/NCBI
|
|
24
|
Siney EJ, Holden A, Casselden E, Bulstrode
H, Thomas GJ and Willaime-Morawek S: Metalloproteinases ADAM10 and
ADAM17 mediate migration and differentiation in glioblastoma
sphere-forming cells. Mol Neurobiol. Aug 19–2016.(Epub ahead of
print). PubMed/NCBI
|
|
25
|
Zepeda-Nuño JS, Guerrero-Velázquez C, Del
Toro-Arreola S, Vega-Magaña N, Ángeles-Sánchez J, Haramati J,
Pereira-Suárez AL and Bueno-Topete MR: Expression of ADAM10, Fas,
FasL and soluble FasL in patients with oral squamous cell carcinoma
(OSCC) and their association with clinical-pathological parameters.
Pathol Oncol Res. 23:345–353. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Detre S, Jotti Saclani G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Graham JK, Kunze E and Hammerstedt RH:
Analysis of sperm cell viability, acrosomal integrity, and
mitochondrial function using flow cytometry. Biol Reprod. 43:55–64.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kalluri R: EMT: When epithelial cells
decide to become mesenchymal-like cells. J Clin Invest.
119:1417–1419. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reiss K and Saftig P: The ‘a disintegrin
and metalloprotease’ (ADAM) family of sheddases: Physiological and
cellular functions. Semin Cell Dev Biol. 20:126–137. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weber S and Saftig P: Ectodomain shedding
and ADAMs in development. Development. 139:3693–3709. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sahin U, Weskamp G, Kelly K, Zhou HM,
Higashiyama S, Peschon J, Hartmann D, Saftig P and Blobel CP:
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six
EGFR ligands. J Cell Biol. 164:769–779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Tetering G, van Diest P, Verlaan I,
van der Wall E, Kopan R and Vooijs M: Metalloprotease ADAM10 is
required for Notch1 site 2 cleavage. J Biol Chem. 284:31018–31027.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu S, Zhang W, Liu K, Ji B and Wang G:
Silencing ADAM10 inhibits the in vitro and in vivo
growth of hepatocellular carcinoma cancer cells. Mol Med Rep.
11:597–602. 2015.PubMed/NCBI
|
